Evaluation of the need for pharmacogenomics testing among physicians in the West Bank of Palestine.
West Bank of Palestine
education
pharmacogenomics
physicians
questionnaire
Journal
Drug metabolism and personalized therapy
ISSN: 2363-8915
Titre abrégé: Drug Metab Pers Ther
Pays: Germany
ID NLM: 101653409
Informations de publication
Date de publication:
04 Jun 2021
04 Jun 2021
Historique:
received:
12
03
2021
accepted:
19
04
2021
entrez:
4
6
2021
pubmed:
5
6
2021
medline:
5
6
2021
Statut:
aheadofprint
Résumé
Pharmacogenomics (PGx) testing optimizes pharmacotherapy and reduces interindividual variation in drug responses. However, it is still not implemented in clinical practice in the West Bank of Palestine (WBP). The aim of this study was to determine the need for PGx education and testing among physicians from different specialties in WBP. This study used a cross-sectional survey that was administered to 381 physicians from different cities in WBP. The questionnaire consisted of 27 closed-ended questions that evaluate the exposure and attitude toward PGx education, the role of PGx testing in clinical practice, and the capabilities of physicians in PGx testing. It was found that exposure to PGx education is low, with most of the respondents (81.1%) answering that PGx was not an integral part of their medical education. The majority (>90%) of the participants agreed that PGx should be included in the medical school curriculum. It was also found that 58.5% of the participants agreed that PGx testing is relevant to their current clinical practice. In addition, most of the participant physicians (>60%) think that they are currently not capable of prescribing and making decisions for pharmacotherapy based on PGx testing. It is concluded that there is a high need for PGx education and implementation in clinical practice in WBP. We recommend adding PGx courses to the curricula of medical schools and going forward with the implementation of PGx testing in clinical practice in WBP.
Identifiants
pubmed: 34087962
pii: dmdi-2021-0121
doi: 10.1515/dmdi-2021-0121
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2021 Walter de Gruyter GmbH, Berlin/Boston.
Références
Ventola, CL. Role of pharmacogenomic biomarkers in predicting and improving drug response: part 1: the clinical significance of pharmacogenetic variants. Pharm Therapeut 2013;38:545–60.
Aneesh, TP, Sekhar M, S, Jose, A, Chandran, L, Zachariah, SM. Pharmacogenomics: the right drug to the right person. J Clin Med Res 2009;1:191–4. https://doi.org/10.4021/jocmr2009.08.1255.
Fung, E, Patsopoulos, NA, Belknap, SM, O’Rourke, DJ, Robb, JF, Anderson, JL, et al.. Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Semin Thromb Hemost 2012;38:893–904. https://doi.org/10.1055/s-0032-1328891.
Schulz, C, Boeck, S, Heinemann, V, Stemmler, HJ. UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy? Anti Canc Drugs 2009;20:867–79. https://doi.org/10.1097/cad.0b013e328330c7d2.
Kaniwa, N, Saito, Y. Pharmacogenomics of severe cutaneous adverse reactions. Pharmacogenomics 2013;14:595–8. https://doi.org/10.2217/pgs.13.27.
Gervasini, G, Benitez, J, Carrillo, JA. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol 2010;66:755–74. https://doi.org/10.1007/s00228-010-0857-7.
Caudle, KE, Gammal, RS, Whirl-Carrillo, M, Hoffman, JM, Relling, MV, Klein, TE. Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am J Health Syst Pharm 2016;73:1977–85. https://doi.org/10.2146/ajhp150977.
Rissmann, R, Dubois, EA, Franson, KL, Cohen, AF. Concept-based learning of personalized prescribing. Br J Clin Pharmacol 2012;74:589–96. https://doi.org/10.1111/j.1365-2125.2012.04270.x.
Shastry, BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J 2006;6:16–21. https://doi.org/10.1038/sj.tpj.6500338.
Frigon, MP, Blackburn, ME, Dubois-Bouchard, C, Gagnon, AL, Tardif, S, Tremblay, K. Pharmacogenetic testing in primary care practice: opinions of physicians, pharmacists and patients. Pharmacogenomics 2019;20:589–98. https://doi.org/10.2217/pgs-2019-0004.
Penas, LE, Teran, E, Sosa-Macias, M, Galaviz-Hernandez, C, Gil, JP, Nair, S, et al.. Challenges and opportunities for clinical pharmacogenetic research studies in resource-limited settings: conclusions from the Council for International Organizations of Medical Sciences-Ibero-American Network of Pharmacogenetics and Pharmacogenomics meeting. Clin Therapeut 2020;42:1595–610. https://doi.org/10.1016/j.clinthera.2020.06.008.
Al-Ramahi, R, Hmedat, B, Alnjajrah, E, Manasrah, I, Radwan, I, Alkhatib, M. Medication dosing errors and associated factors in hospitalized pediatric patients from the South Area of the West Bank - Palestine. Saudi Pharmaceut J 2017;25:857–60. https://doi.org/10.1016/j.jsps.2017.01.001.
McCullough, KB, Formea, CM, Berg, KD, Burzynski, JA, Cunningham, JL, Ou, NN, et al.. Assessment of the pharmacogenomics educational needs of pharmacists. Am J Pharmaceut Educ 2011;75:51. https://doi.org/10.5688/ajpe75351.
AlEjielat, R, Ejielat, Z, Andrawes, S, Mhaidat, NM. An evaluation of the knowledge, opinions, expectations and concerns toward pharmacogenomics among Jordanian pharmacists. Pers Med 2016;13:143–54. https://doi.org/10.2217/pme.15.50.
WW D. Biostatistics, a foundation for analysis in the health sciences. New York: Wiley; 1987, vol 4th ed.
Sampling methods in morbidity surveys and public health investigations. Tenth report of the WHO Expert Committee on Health Statistics. World Health Organ Tech Rep Ser 1966;336:1–31.
Karas Kuzelicki, N, Prodan Zitnik, I, Gurwitz, D, Llerena, A, Cascorbi, I, Siest, S, et al.. Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey. Pharmacogenomics 2019;20:643–57.
Gurwitz, D, Lunshof, JE, Dedoussis, G, Flordellis, CS, Fuhr, U, Kirchheiner, J, et al.. Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J 2005;5:221–5. https://doi.org/10.1038/sj.tpj.6500312.
Kim, WY, Kim, HS, Oh, M, Shin, JG. Survey of physicians’ views on the clinical implementation of pharmacogenomics-based personalized therapy. Transl Clin Pharmacol 2020;28:34–42. https://doi.org/10.12793/tcp.2020.28.e6.
El Shamieh, S, Zgheib, NK. Pharmacogenetics in developing countries and low resource environments. Hum Genet 2021. https://doi.org/10.1007/s00439-021-02260-9.
Jarrar, Y, Mosleh, R, Hawash, M, Jarrar, Q. Knowledge and attitudes of pharmacy students towards pharmacogenomics among universities in Jordan and West Bank of Palestine. Pharmacogenomics Personalized Med 2019;12:247–55. https://doi.org/10.2147/pgpm.s222705.
Jarrar, Y. Perception of primary care physicians’ toward pharmacogenetics in Jordan. Jordan Med J 2019;53:81–9.
Verbelen, M, Weale, ME, Lewis, CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J 2017;17:395–402. https://doi.org/10.1038/tpj.2017.21.
Jarrar, Y, Musleh, R, Ghanim, M, AbuKhader, I, Jarrar, Q. Assessment of the need for pharmacogenomics education among pharmacists in West Bank of Palestine. Int J Clin Pract 2021, in press.
Becker, DE. Adverse drug reactions in dental practice. Anesth Prog 2014;61:26–33. https://doi.org/10.2344/0003-3006-61.1.26.